SEC Form 3 · accession 0001209191-15-039629
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Holly D. Chrzanowski
Officer — See Remarks
Period of report
May 6, 2015
Accepted (ET)
May 6, 2015 · 8:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,885 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.72 | holding | — | — | — | — | Dec 14, 2020 | Common Stock | 5,028 | — | D |
| Stock Option (right to buy)F2 | $0.72 | holding | — | — | — | — | Jun 2, 2021 | Common Stock | 1,508 | — | D |
| Stock Option (right to buy)F3 | $0.88 | holding | — | — | — | — | Sep 13, 2022 | Common Stock | 14,715 | — | D |
| Stock Option (right to buy)F4 | $4.06 | holding | — | — | — | — | Jun 28, 2023 | Common Stock | 20,403 | — | D |
| Stock Option (right to buy)F5 | $4.06 | holding | — | — | — | — | Mar 5, 2024 | Common Stock | 4,400 | — | D |
| Stock Option (right to buy)F6 | $9.15 | holding | — | — | — | — | Apr 17, 2025 | Common Stock | 8,800 | — | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on December 14, 2010. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F2The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on January 1, 2011. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F3The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on September 13, 2012. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F4The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on April 29, 2013. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F5The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on January 1, 2014. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F6The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on April 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Remarks
Vice President, Enterprise Talent and Organization Exhibit List Exhibit 24.1 - Power of Attorney